ArticleRespiratory research2025
TRANS: a prediction model for EGFR mutation status in NSCLC based on radiomics and clinical features.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Radiomics to understand pre-treatment tumor biology for resectable non-small cell lung cancer.Frontiers in oncology · 2026Review
- Cost-Efficient Early Diagnostic Tool for Lung Cancer: Explainable AI in Clinical Systems.Technology in cancer research & treatmentArticle
- Explainable 1-mm Peritumoral CT Radiomics forCancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly detection of epidermal growth factor receptor (EGFR) is critical for guiding therapeutic decisions in non-small-cell lung cancer (NSCLC). The study aims to develop a predictive model for EGFR mutations with multicohort data.
methodsThe study enrolled 254 NSCLC patients of four cohorts: the Affiliated Hospital of Qingdao University (AHQU, n = 54), the Second Affiliated Hospital of Soochow University (SAHSU, n = 78), TCGA-NSCLC (n = 91), and CPTAC-NSCLC (n = 31). Radiomic features were extracted using the LIFEx software. The least absolute shrinkage and selection operator (LASSO) algorithm was utilized to select predictive features of CT radiomics, clinical data, and RNA sequencing, which were evaluated using receiver operating characteristic (ROC) curves. A nomogram was developed by integrating predictive features. Biological functions were analyzed utilizing RNA sequencing data.
resultsEight radiomic features, four clinical features, and seven genomic features were selected to construct distinct signatures. Through internal 5-fold cross-validation, the first two signatures demonstrated notable discrimination capabilities for distinguishing between mutated and wild-type EGFR, resulting in area under the curve (AUC) values of 0.79 (± 0.08) and 0.74 (± 0.06), respectively. The combination of clinical variables and radiomics signature resulted in an increased AUC of 0.84 (± 0.01). This combined model was named TRANS, representing TTF-1, radiomic signature, AE1/AE3, NapsinA, and stage, which uses radiomics and routine immunohistochemistry markers as inputs. High-risk TRANS was observed to be associated with poor overall survival, and showed relationships with high T cell infiltration and response to PD-1 immunotherapy.
conclusionsThe TRANS model demonstrated favorable ability in predicting EGFR mutation status in NSCLC, providing a valuable approach for optimizing therapeutic strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.